EP Patent

EP2270014A1 — Azepine inhibitors of janus kinases

Assigned to Incyte Corp · Expires 2011-01-05 · 15y expired

What this patent protects

The invention provides compounds that modiste the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other disease…

USPTO Abstract

The invention provides compounds that modiste the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP2270014A1
Jurisdiction
EP
Classification
—
Expires
2011-01-05
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.